AVEO Pharmaceuticals (NASDAQ:AVEO) Receives Media Impact Rating of 0.22

News headlines about AVEO Pharmaceuticals (NASDAQ:AVEO) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.757543991838 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Shares of AVEO stock traded up $0.09 on Wednesday, reaching $3.00. The company’s stock had a trading volume of 2,211,705 shares, compared to its average volume of 1,716,711. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of -0.45. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $4.24. The stock has a market cap of $345.90, a P/E ratio of -4.17 and a beta of 1.38.

Several equities research analysts recently weighed in on the company. B. Riley restated a “buy” rating and set a $5.00 target price on shares of AVEO Pharmaceuticals in a report on Tuesday, January 16th. BidaskClub raised AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Finally, Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. AVEO Pharmaceuticals has a consensus rating of “Hold” and an average target price of $4.05.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/03/21/aveo-pharmaceuticals-aveo-given-news-impact-score-of-0-22/1923606.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.